SCHEMBL5723031

SCHEMBL5723031

COC(=O)c1ccc(OC)c2c1OC1(CCCC1)C2

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 9/20 0.42
PDE4B Q07343 9/20 0.42
PDE4C Q08493 9/20 0.42
PDE4D Q08499 9/20 0.42
KDM4E B2RXH2 5/20 0.37
ALDH1A1 P00352 3/20 0.37
HSD17B10 Q99714 2/20 0.37
HPGD P15428 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
LMNA P02545 2/20 0.37
CETP P11597 1/20 0.36
CASP1 P29466 2/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
CASP7 P55210 1/20 0.34
TSHR P16473 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5722999 0.90 PDE4A (0.47) PDE4APDE4BPDE4CPDE4DKDM4E
SCHEMBL5723198 0.88 PDE4A (0.46) PDE4APDE4BPDE4CPDE4DKDM4E
SCHEMBL5722892 0.88 PDE4A (0.43) PDE4APDE4BPDE4CPDE4DKDM4E
SCHEMBL8939971 0.82 FFAR4 (0.41) KDM4EALDH1A1HSD17B10HPGDSMN1; SMN2
SCHEMBL5723253 0.82 PDE4D (0.40) PDE4APDE4BPDE4CPDE4DKDM4E
SCHEMBL5722745 0.81 PDE4D (0.39) PDE4APDE4BPDE4CPDE4DKDM4E
SCHEMBL5722858 0.81 PKM (0.50) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL5723080 0.80 LMNA (0.50) PDE4APDE4BPDE4CPDE4DKDM4E
SCHEMBL5723309 0.78 PDE4A (0.41) PDE4APDE4BPDE4CPDE4DSMN1; SMN2
SCHEMBL5723044 0.78 PDE4D (0.55) PDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0771794-B1 OXYGEN-CONTAINING HETEROCYCLIC COMPOUNDS KYOWA HAKKO KOGYO KK (JP) 2006-05-03 EP disclosed
US-6716987-B1 PHOSPHODIESTERASE IV INHIBITORS KYOWA HAKKO KOGYO CO., LTD. (JP) 2004-04-06 US disclosed
US-6514996-B2 Derivatives of benzofuran or benzodioxole KYOWA HAKKO KOGYO CO., LTD. (JP) 2003-02-04 US disclosed
US-20020128290-A1 DERIVATIVES OF BENZOFURAN OR BENZODIOXOLE KYOWA HAKKO KOGYO CO., LTD. (JP) 2002-09-12 US disclosed
EP-0771794-A1 OXYGEN-CONTAINING HETEROCYCLIC COMPOUNDS KYOWA HAKKO KOGYO CO., LTD. (JP) 1997-05-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020128290-A1 DERIVATIVES OF BENZOFURAN OR BENZODIOXOLE CBR1, CBR3, CYC1 PDE4A 4879/4885PDE4B 4877/4885PDE4C 4882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.